The Food and Drug Administration (FDA) has approved Tibsovo® (ivosidenib) in combination with azacitidine for newly diagnosed acute myeloid leukemia (AML) with an IDH1 mutation, as detected by an FDA-approved test, in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.

The approval was based on data from the phase 3 AGILE trial (ClincialTrials.gov Identifier: NCT03173248). The trial included 146 patients with newly diagnosed AML and an IDH1 mutation who met at least 1 of the following criteria: age 75 years or older, baseline Eastern Cooperative Oncology Group performance status of 2, severe cardiac or pulmonary disease, hepatic impairment with bilirubin less than 1.5 times the upper limit of normal, creatinine clearance greater than 45mL/min, or other comorbidity. 

Patients were randomly assigned to receive ivosidenib at 500 mg or placebo orally once daily on days 1 to 28 in combination with azacitidine at 75 mg/m2/day either subcutaneously or intravenously on days 1 to 7 (or days 1 to 5 and 8 to 9) of each 28 days cycle beginning on cycle 1 day 1. Study participants received a minimum of 6 cycles of treatment unless they experienced disease progression, had unacceptable toxicity, or underwent hematopoietic stem cell transplant.


Continue Reading

The primary endpoint of the study was event free survival (EFS), defined as the time from randomization until treatment failure (failure to achieve complete remission by week 24), relapse from remission, or death from any cause, whichever occurred first.

Results showed a statistically significant improvement in EFS (hazard ratio [HR], 0.35; 95% CI 0.17-0.72; P = .0038) and overall survival (OS; HR, 0.44; 95% CI 0.27-0.73; P = .0010) with ivosidenib plus azacitidine compared with placebo plus azacitidine. EFS events occurred in 65% of patients in the ivosidenib arm and 84% of patients in the placebo arm.

The median OS was 24.0 months (95% CI, 11.3-34.1) and 7.9 months (95% CI, 4.1-11.3) in the ivosidenib plus azacitidine and placebo plus azacitidine groups, respectively (HR 0.44; 95% CI, 0.27-0.73; P =.0010).

Complete remission (CR) was 47% (95% CI, 35-59) with ivosidenib plus azacitidine and 15% (95% CI, 8-25) with placebo plus azacitidine. The median duration of CR was not estimable (NE) in the ivosidenib plus azacitidine group (95% CI, 13.0, NE) and 11.2 months (95% CI, 3.2, NE) in the placebo plus azacitidine group. The median time to first CR for ivosidenib with azacitidine was 4 months (range, 1.7-11.9).

The new indication for AML expands on a previously approved monotherapy regimen for patients with newly diagnosed AML with IDH1 mutation. Tibsovo is also approved to treat refractory AML and cholangiocarcinoma.

References

  1. Servier Announces FDA approval of Tibsovo® (ivosidenib tablets) in combination with azacitidine for patients with newly diagnosed IDH1-mutated acute myeloid leukemia. News release. May 25, 2022. https://www.prnewswire.com/news-releases/servier-announces-fda-approval-of-tibsovo-ivosidenib-tablets-in-combination-with-azacitidine-for-patients-with-newly-diagnosed-idh1-mutated-acute-myeloid-leukemia-301555363.html
  2. Tibsovo. Package insert. Servier; 2022. Accessed May 26, 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211192s009lbl.pdf

This article originally appeared on MPR